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A genotoxic carcinogen, N-nitrosodimethylamine (NDMA), was detected as a synthe-
sis impurity in some valsartan drugs in 2018, and other N-nitrosamines, such as
N-nitrosodiethylamine (NDEA), were later detected in other sartan products. N-
nitrosamines are pro-mutagens that can react with DNA following metabolism to pro-
duce DNA adducts, such as O6-alkyl-guanine. The adducts can result in DNA replica-
tion miscoding errors leading to GC>AT mutations and increased risk of genomic
instability and carcinogenesis. Both NDMA and NDEA are known rodent carcinogens
in male and female rats. The DNA repair enzyme, methylguanine DNA-
methyltransferase can restore DNA integrity via the removal of alkyl groups from
guanine in an error-free fashion and this can result in nonlinear dose responses and a
point of departure or “practical threshold” for mutation at low doses of exposure.
Following International recommendations (ICHM7; ICHQ3C and ICHQ3D), we calcu-
lated permissible daily exposures (PDE) for NDMA and NDEA using published rodent
cancer bioassay and in vivo mutagenicity data to determine benchmark dose values
and define points of departure and adjusted with appropriate uncertainty factors
(UFs). PDEs for NDMA were 6.2 and 0.6 μg/person/day for cancer and mutation,
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respectively, and for NDEA, 2.2 and 0.04 μg/person/day. Both PDEs are higher than
the acceptable daily intake values (96 ng for NDMA and 26.5 ng for NDEA) calcu-
lated by regulatory authorities using simple linear extrapolation from carcinogenicity
data. These PDE calculations using a bench-mark approach provide a more robust
assessment of exposure limits compared with simple linear extrapolations and can
better inform risk to patients exposed to the contaminated sartans.
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1 | INTRODUCTION
N-Alkyl-nitrosamines, such as N-nitrosodimethylamine (NDMA) and N-
nitrosodiethylamine (NDEA), are well-studied environmental mutagens.
These substances are known genotoxic carcinogens in the rat; the most
comprehensive carcinogenicity dose–response data available indicates
liver as the most sensitive target for tumorigenicity (Peto et al., 1991).
Both nitrosamines require metabolic activation by CYP2E1, which has
high inducible levels within the liver (Encell et al., 1996).
Nitrosamines are known to be metabolized to DNA reactive muta-
gens that result in methylation (alkylation) at the O6 position of guanine
(Arimoto-Kobayashi et al., 1997), the O4 position of thymidine (Verna
et al., 1996), and other less mutagenic lesions (Souliotis et al., 1995).
When left unrepaired, the O6-methyl-guanine can be mistakenly recog-
nized as adenine, causing GC>AT substitution mutations during replica-
tion, and misrecognition of O4-alkyl-thymidine can lead to TA>CG
mutations. The methyl or ethyl group can be removed from O6-alkyl-
guanine or O4-alkyl-thymidine by methylguanine DNA methyltransferase
(MGMT), leaving a normal guanine and thymine residue. MGMT's ability
to remove base alkylations to restore the normal wild-type DNA
sequence represents an error-free DNA damage response (Christmann
et al., 2011; Fahrer et al., 2015; Kaina et al., 1991; Kaina et al., 1993;
Margison et al., 2003; Thomas et al., 2013) that can mechanistically
account for the manifestation of a dose–response threshold. Mutagenic
carcinogens often act via multiple mechanisms. NDMA and NDEA are
also clastogenic along with hepatotoxic, and they can induce secondary
damage via formaldehyde and reactive oxygen species production
(World Health Organization, 2002). However, the most prevalent potent
and cancer-related mechanism is O6-alkyl-guanine adduction.
Dietary exposure to nitrosamines is well recognized with their
presence in cured meats, tobacco smoke, and beer has been recog-
nized for many years (Abdel-Tawab et al., 2018; EMA, 2020a;
Snodin & Elder, 2019). For example, NDMA exposure from dietary
consumption levels range from 0.0004 to 0.23 μg/day from cured
meat, 0.0004 to 1.02 μg/day from smoked meat, and 0.0006 to
0.13 μg/day from grilled meat (FDA, 2018; Snodin & Elder, 2019).
Likewise exposure via drinking water is also recognized, for example
the U.S. Environmental Protection Agency (EPA) has set health refer-
ence levels for NDEA at 0.8 ng/day and NDMA at 0.6 ng/day
(EMA, 2020a).
In addition to environmental exposure, NDMA was recently
detected as a process-related contaminant in the pharmaceutical product
valsartan. In 2018, this led to a global recall of valsartan-containing prep-
arations in more than 22 countries, including Canada (Health
Canada, 2018), Europe (EMA, 2018), and the United States (FDA, 2018).
The impurity was linked to the synthetic process employed by Zhejiang
Huahai Pharmaceuticals in China, a major producer of the active pharma-
ceutical ingredient (API) in valsartan. Certain companies specializing in
producing generic pharmaceuticals purchased this API for inclusion in
their products, and patients consuming the contaminated generic prod-
ucts were inadvertently exposed to NDMA. The U.S. Food and Drug
Administration (FDA) later reported that valsartan manufactured by Het-
ero Labs in India also contained NDMA (Lowe, 2019). Detailed analyses
of valsartan tablets revealed NDMA levels of up to 22 μg per 320-mg
tablet, the highest strength available. It later became apparent that
NDEA was present in the sartan drugs, irbesartan and losartan, man-
ufactured by ScieGen and Zhejiang Huahai Pharmaceuticals, respectively
(Lowe, 2019). For NDEA, 3.7 μg per 320-mg tablet has been used as a
conservative worst case contamination level estimate (EMA, 2019).
The default approach for regulatory evaluation of mutagenic carcino-
gens, such as NDMA and NDEA, is to employ linear low-dose extrapola-
tion from carcinogenicity dose–response data (ICH, 2017; ICH, 2018).
The biology of the linear approach to risk assessment can be traced back
to Muller and Stern (1940ies) as well as Knudson Jr. (1971) and others,
who postulated that a small number of “hits” by mutagenic chemicals or
ionizing radiation are sufficient to cause certain types of cancer. At the
most conservative end of these theories, one molecule of a carcinogen is
capable of causing one adduct, creating one mutation, and one mutated
cancer-related gene that finally leads to cancer.
Since suitable carcinogenicity data are available, the approach
recently used for risk assessment of NDMA was linear extrapolation from
the dose (in milligrams per kilogram per day) resulting in tumor induction
in 50% of the animals (i.e. TD50). More specifically, in response to the
valsartan contamination incident, regulatory authorities used the har-
monic mean TD50 value for liver tumor incidence from studies in the Car-
cinogenic Potency Database (CPDB; 96 μg/kg/day) (Gold, 1980) and
applied linear extrapolation to estimate that excess cancer risk. The values
obtained indicated a theoretical excess lifetime cancer risk of 1 in 8000,
assuming consumption of the highest prescribed dose of valsartan
(320 mg/day), with the highest levels of NDMA, for 4 years (FDA, 2018).
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Similarly, the European Medicines Agency (EMA) stated that consumption
for 7 years would be associated with a theoretical excess lifetime cancer
risk of 1 in 5000. These and similar values calculated by other regulatory
agencies worldwide (e.g., 1 in 11,600 (Health Canada, 2018)) led to a
widespread product recall of sartan products. Similar calculations led to
prohibitions of sartan products containing NDEA (EMA, 2020a).
To calculate a lifetime acceptable intake (AI) on which to base limits
for these nitrosamines in pharmaceuticals, assuming a theoretical excess
cancer incidence of 1 per 100,000, EMA's linear low-dose extrapolation
from the TD50 yielded AI values of 96 ng/person/day for NDMA and
26.5 ng/person/day for NDEA (EMA, 2010). The estimates represent
extremely conservative AI values for human risk assessment, as they do
not consider the full character of the dose–response relationship. These
AI values are also being used as interim general limits for other nitrosa-
mine impurities that lack carcinogenicity data to calculate compound-
specific limits (EMA, 2020b; FDA, 2021). Furthermore, a stricter limit of
0.03 ppm supersedes AIs, based on technical feasibility of the analytical
methods (EMA, 2020a). Not all N-nitrosamines are high-potency muta-
genic carcinogens, based on their harmonic-mean TD50 values covering.
Furthermore, based on the Lhasa data, nearly 20% of nitrosamines appear
to be noncarcinogenic in rodent bioassays (Thresher et al., 2020). There-
fore, it could be argued that N-nitrosamine carcinogenic potency should
be evaluated case by case, rather than assuming that all are of high
potency based on perceptions of the Cohort of Concern.
It is now known that carcinogenesis is a multifactorial process
involving mutagenic and non-mutagenic pathways and importantly the
mutagenic “adverse outcome pathway” is not linear, with molecular initi-
ating events (adducts) and key events (mutations) being repaired and/or
simply not leading to a deleterious effect (Yauk et al., 2015). Further-
more, it is increasingly accepted that threshold mechanisms exist for
mutagenic carcinogens (MacGregor et al., 2015a, 2015b) and an exten-
sive analysis of carcinogens has showed that “at non-toxic doses”
thresholds exist for the induction of experimental cancer for all types of
carcinogen, including NDMA (Kobets & Williams, 2019).
DNA repair proficiency has been shown to have a measurable and
consistent effect on the position of the PoD, through repair of low levels
of specific adducts and mutations (White et al., 2020). For many nitrosa-
mine induced adducts, MGMT is the key DNA repair enzyme, which is
known to have a background level of approximately 200 molecules per
cell, and is also inducible in rats (Kaina et al., 1993; Souliotis et al., 1998)
but this is yet to be shown in human cells (Fritz & Kaina, 1992).
Terminology around the background levels of adducts and muta-
tions, must be clearly defined when using mutation data for risk
assessment purposes. Endogenous sources of DNA damage are
defined here as including reactive oxygen species, formaldehyde, as
well as sources such as gut nitrosation and cellular metabolism. Exoge-
nous sources can be divided into two distinct categories, which are
from environmental exposures including food and water, or from
drug-related factors including impurities. Endogenous damage is not
fully considered with the linear approach.
In addition to the biological issues, there are also several deficiencies
observed when applying the linear extrapolation approach, although it is a
pragmatic approach for estimating de minimis risk of mutagenic
carcinogens. First, the default replicate number in a cancer bioassay is
50 animals per dose group per sex, and numbers of tumors may be small.
Thus, extrapolating from the TD50 potency estimate to a dose theoreti-
cally associated with a cancer risk of 1 in 100,000 or 1 in 1,000,000 con-
flicts with the statistical power of the standard study design, and it does
not consider the substantial errors associated with the estimate of the
TD50. Second, adjustment factors are not included in the linear extrapola-
tion, meaning that the resulting excess cancer risk relates to the test spe-
cies population and not the human population, which may be more or
less susceptible than the test species. Third, confidence intervals (CIs) are
not used; as the uncertainty in a cancer risk estimates may be huge; thus
single value estimates of cancer risk are essentially meaningless since they
do not account for innate biological variation (Slob et al., 2014).
There is an alternative to the linear low-dose extrapolation approach
based on rodent carcinogenic potency (e.g., TD50) based on the use of
quantitative interpretation of in vivo mutagenicity dose–response data
for risk assessment and regulatory decision-making (Benford, 2015;
Gollapudi et al., 2013; Heflich et al., 2020; Johnson et al., 2014; Labash
et al., 2015; MacGregor et al., 2015b; White et al., 2020; White &
Johnson, 2016). Such an approach is particularly relevant for other impuri-
ties, where carcinogenicity data are unavailable or of poor quality, and
existing in vivo mutagenicity dose–response data display a mechanistically
understood response threshold (COM, 2018). More specifically, quantita-
tive analyses of in vivo mutagenicity dose–response data can be used to
determine a dose below which the likelihood of a response at a key event
along the “Adverse Outcome Pathway” (AOP) in the test animal is negligi-
ble (i.e., a point of departure [PoD] such as the no observed effect level
[NOEL], threshold dose [Td], or benchmark dose [BMD]). The mutation
data are from somatic cells, which link to the adverse outcome of cancer,
however, inclusion of germ cell mutation data, when available, would
allow for assessment of heritable mutations in offspring as the adverse
outcome (Cliet et al., 1993; Heflich et al., 2020).
Subsequently, the use of uncertainty factors (UFs), can be used to
determine a regulatory human exposure limit, including health-based
guidance values (HBGVs) such as AI or permissible daily exposure
(PDE). They are also sometimes referred to as extrapolation or adjust-
ment factors (White et al., 2020) of uncertainty or modifying factors
(ICHQ3C and ICHM7 metrics such as the NOEL or BMD, which are
indicative of compound potency.
With respect to quantitative dose–response analyses for the
determination of mutagenic potency, several authors have highlighted
advantages of the BMD approach (Hardy et al., 2017; Johnson
et al., 2014; White et al., 2020; Wills et al., 2016). For example, it is
essential that a PoD should have a measure of precision or uncer-
tainty (Slob, 2014a; Slob, 2014b), and the BMD has CIs; however, the
NOEL does not. Furthermore, the NOEL is heavily dependent on
experimental conditions, and the BMD is to a much lesser extent
(MacGregor et al., 2015a, 2015b). Johnson et al. (2014) conservatively
used the lowest in vivo mutagenicity benchmark dose (BMD lower
bound [BMDL]) to determine a regulatory exposure limit for the
potent alkylating agents N-methyl-N-nitrosourea (MNU) and N-ethyl-
N-nitrosourea (ENU), and since that time, this approach has been used
in case studies and regulatory submissions and with other genotoxic
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compounds (Gollapudi et al., 2020; Luijten et al., 2020; Kirkland
et al., 2021).
Formal deployment of quantitative methods for interpretation of
mutagenicity dose–response data was pioneered by F. Hoffmann-La
Roche AG following an incident that resulted in the inadvertent patient
exposure to the mutagenic alkylating agent ethylmethanesulfonate
(EMS) (Gocke et al., 2009b, 2009c; Muller et al., 2009; Muller &
Gocke, 2009). In the absence of carcinogenicity data, detailed analyses
of transgenic rodent (TGR) mutagenicity dose–response data (using
MutaMouse) were used to determine NOEL and Td values and mode-
of-action mechanisms to support a threshold-based risk assessment.
Their studies were used to define (a) safety factors differentiating the
NOEL and the maximum human exposure level in patients who had
received EMS-contaminated nelfinavir (Viracept; later shown to be a
454-fold safety margin) (Muller et al., 2009) and (b) a regulatory exposure
limit below which the likelihood of a mutagenic effect was considered
negligible (i.e., the PDE) (Gocke et al., 2009a; Gocke & Wall, 2009;
Muller & Gocke, 2009). Application of the quantitative paradigm for reg-
ulatory interpretation of the MutaMouse dose–response data was
supported by evidence for a true or practical threshold response based
on error-free DNA repair by MGMT of the pro-mutagenic O6-ethyl-
guanine adducts (Muller et al., 2009). More recently, an analogous use of
the PDE has been proposed to determine exposure limit values for phar-
maceutical impurities, including DNA-reactive mutagens (Bercu
et al., 2018). Such applications are in accordance with the following
statement in the ICH M7 guideline:
[T]he existence of mechanisms leading to a dose
response that is non-linear or has a practical threshold
is increasingly recognized, not only for compounds that
interact with non-DNA targets but also for DNA-
reactive compounds, whose effects may be modulated
by, for example, rapid detoxification before coming
into contact with DNA, or by effective repair of
induced damage. The regulatory approach to such
compounds can be based on the identification of a No-
Observed Effect Level (NOEL), and use of uncertainty
factors (see ICH Q3C(R5)) to calculate a PDE when
data are available. (ICH, 2017)
Although regulatory authorities generally use the linear extrapola-
tion approach to ensure the safety of a population exposed to a DNA-
reactive carcinogen, its application for NDMA and NDEA does not
acknowledge the fundamental scientific shift in the quantitative
approaches now advocated for regulatory interpretation of mutagenicity
dose–response data (Heflich et al., 2020; White et al., 2020). Further-
more, NDEA has been shown to exhibit a potential ‘threshold’ for carci-
nogenicity (Waddell et al., 2006). Indeed, the current position on
nitrosamines in drug product do not utilize ICH M7 guideline options for
instances when DNA repair mechanisms (i.e., those that can lead to com-
pensatory responses at low dose exposures) are well documented
(ICH, 2017). The options specified in the ICH M7(R1) guideline are to
(a) carry out a linear extrapolation from the TD50 to calculate an AI;
(b) apply the threshold of toxicological concern (TTC) when suitable car-
cinogenicity data are not available; or (c) utilize available information
about compensatory responses (e.g., DNA repair) to justify derivation of
a PDE, the term used in ICH guidelines when nonlinear dose response is
accepted (ICH, 2017). In the absence of carcinogenicity data or when
such data are not sufficiently robust, the generation and analysis of
in vivo mutagenicity dose–response data provides a pragmatic means for
determination of a compound-specific AI/PDE. Due to the difficulty and
cost of performing carcinogenicity studies, it is interesting to note that
the EMA article 5(3) review (EMA, 2020b) recommends performing TGR
mutation studies rather than carcinogenicity studies for N-nitrosamine
impurities and using in vivo mutagenicity dose–response data to deter-
mine a BMD as the PoD for risk estimation (EMA, 2020b).
The liver was also shown to be the most sensitive tissue for
induction of gene mutations in rats and mice (Akagi et al., 2015;
Gollapudi et al., 1998; Jiao et al., 1997). Therefore, the rat study can-
cer and mutation data were selected for BMD analysis and PDE calcu-
lations enabling comparison of PDEs for cancer and mutation in the
same species (Akagi et al., 2015; Gollapudi et al., 1998). We have ana-
lyzed NDMA and NDEA dose response data to determine BMDs for
each nitrosamine based on existing data and applied various adjust-
ment factors to calculate safe human exposure limits and PDEs. The
analysis also provides an opportunity to compare PDE exposure limits
derived from in vivo mutagenicity data with those from cancer-studies
for both compounds and thereby build on the experience with the use
of mutagenicity data for BMD based risk assessments. The values are
subsequently evaluated via comparisons with the default TTC for
non-nitrosamines as well as for known or estimated human exposures
to nitrosamines via foods or therapeutic products (e.g., valsartan).
2 | MATERIALS AND METHODS
2.1 | Data selection
A literature review and analysis of the Carcinogenic Potency Database
(CPDB) (Gold, 1980) now located at Lhasa (Leeds UK) (Lhasa, 2020)
was carried out in order to identify the most suitable carcinogenicity
data for BMD analysis. Dose spacing, total animal number, and
detailed tumor analysis were considered when selecting the most rel-
evant rodent cancer bioassay data for BMD analysis. Mutation is con-
sidered to be the most relevant key event in the AOP for cancer
induced by alkylating agents, such as NDEA and NDMA, and a review
of published literature was carried out to find the most suitable
in vivo mutation data for both compounds. Selection criteria included
the number of dose levels and replicates used since these variables
are important for BMD precision.
The most extensive carcinogenicity dose–response data for
NDMA and NDEA were identified in a study by Peto et al. (1991) con-
ducted in inbred Colworth/Wistar rats. Data that has been previously
used for a food-based risk assessment of nitrosamine cancer risk
(Zeilmaker et al., 2010). The study included 15 doses plus vehicle con-
trols, with 60 animals per dose group for each sex and 240 animals
296 JOHNSON ET AL.
per vehicle control group. The liver was the most sensitive tissue and
was defined as the most relevant tissue for the present analysis. Liver
tumor data were expressed as the total numbers of malignant tumors
from the different tumor types presented (Kupffer, bile duct, mesen-
chymal, and “liver cell”). The frequency of neoplasms observed at the
lowest six doses was indistinguishable from that in the vehicle control
animals (Peto et al., 1991). For our analyses, malignant cancer data
(see Table 7 of Peto et al. (1991)) were used to assess the “extra risk”
at the time of sampling.
TGR gene mutation data for both nitrosamines were reviewed
to identify studies that had sampled liver. Although numerous stud-
ies were identified, none met OECD 488 recommendations for
study design (OECD, 2011). The most suitable in vivo mutagenicity
data for NDMA (4 doses) were published by Gollapudi et al. (1998)
using the LacI gene in Big Blue rats and for NDEA (3 doses) by
Akagi et al. (2015) using the gpt gene in rats. The studies included
vehicle controls and the liver was the most sensitive tissue. For
Gollapudi et al. (1998), four animals per dose were used, with daily
oral gavage dosing on test days 1–5 and 8–11; animals were
sacrificed on test day 12, with selected tissues collected and stored
for analysis. Akagi et al. (2015) used five animals per dose across
F344 and Sprague Dawley (SD) rats (NDEA was dissolved in drink-
ing water), and animals were sacrificed at 2, 4, or 8 weeks. These
studies might be repeated using the recommended study require-
ment of OECD 488 (OECD, 2011), which could increase the preci-
sion and acceptance of the BMD CI and associated PDE's. Other
studies were rejected as inadequate, with too few dose levels
(Ashby et al., 1994; Souliotis et al., 1998; Suzuki et al., 1996) or the
exposure, expression, or recovery periods were too short
(Butterworth et al., 1998; Jiao et al., 1997). Studies of a different
mutation target, the Pig-a gene, using circulating red blood cells
(Dertinger et al., 2019) were also considered; however, for these
metabolically activated mutagens, mutations in liver cells of the
transgenic rodents were considered the most relevant endpoint for
derivation of a PDE based on mutagenicity-data.
2.2 | BMD analyses
The BMD application software (PROAST v69.2) was used to analyze
and interpret the mutagenicity and carcinogenicity dose–response
data for both NDEA and NDMA. The TGR mutant frequency data are
continuous, and the default analyses selected were therefore the Hill
and exponential models (EFSA, 2009; Hardy et al., 2017; Slob &
Setzer, 2014). The combined analyses for the Akagi et al. (2015)
NDEA TGR data assumed that the shape parameters (i.e., the maxi-
mum response [parameter c] and log-steepness [parameter d]) were
equal for all subgroups, whereas the background response (parameter
a), potency (parameter b), and within-group variation (var) were tested
for subgroup dependence (Slob & Setzer, 2014; Wills et al., 2016). A
critical effect size (CES) of 50% was used for the in vivo TGR mutage-
nicity data based on previous recommendations (Zeller et al., 2017);
thus, BMDL50 values were determined for NDEA mutagenicity data.
For the analysis of the carcinogenicity dose response data (i.e., a
quantal endpoint), a CES of 10% extra risk was employed
(EFSA, 2009; EPA, 2012; Hardy et al., 2017). Model averaging was
used to derive the BMD and associated CI values across the suite of
relevant models: two stage, log probit, probit, log logistic, logistic,
gamma, exponential, Weibull, and Hill (EFSA, 2009; EPA, 2018; Hardy
et al., 2017). By default in PROAST, all converged models are consid-
ered for model averaging, but for each response the user can change
the set of models to be considered (EFSA, 2019). The bootstrap
approach was used to examine the BMD sampling distributions and
precision. The default number of bootstrap runs for calculating the
BMD CIs was set to the default of 200 (Slob, 2018). Previous BMD
analyses on these NDMA and NDEA cancer data, were carried out
using the standard BMD approach for quantal data (EC, 2012), as
model averaging was not an option at that time of analysis. Further-
more, malignant cancers were assessed here, as this was the most
appropriate adverse outcome for comparison to the mutation BMD CI
and PDE.
2.3 | Calculation of PDEs
PDE values were calculated according to the formula outlined in ICH
M7 (ICH, 2017), with the exception that BMDL was used in place of a
no observed adverse effect level (NOAEL) (Hardy et al., 2017). The
lower bound of the BMDL represents a conservative estimate for
the PoD calculation and this has advantages compared to the NOEL
(Hardy et al., 2017). For example, a PoD should have CIs as a measure
of precision and also be minimally affected by dose selection
(MacGregor et al., 2015a, 2015b). PDE values were calculated




where the default body weight was 50 kg, the value used by ICH for
conservative evaluations of pharmaceutical impurities (Bercu
et al., 2018).
The uncertainty/modifying factors (i.e., F1–F5, according to the
nomenclature used in ICH Q3) used the following specifications
ICH (2018):
• F1: species extrapolation values employed to determine the human
equivalent dose. The analyses here employed a default value of
5 for rats based on standard allometric scaling factors.
• F2: interindividual variability. A maximum value of 10 was used to
reflect the assumed variability in DNA repair proficiency as the
major factor. Support for including a high value for F2 comes from
a study comparing the BMD CI in multiple test systems, including
wild-type versus repair-deficient mammalian cell test systems, with
the ratio of BMD supporting the value of 10 (White et al., 2020).
• F3: exposure duration. A factor of 1 was used for the long-term
study duration (over 1 year of continuous exposure in rodents
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(Peto et al., 1991)) cancer bioassay data, and a factor of 10 was
used for the TGR mutagenicity data (ICH, 2017). The TGR mutage-
nicity studies were 12 days for NDMA, along with 14, 28, and
56 days for NDEA. Since there is currently no accepted basis for
extrapolating the duration of the mutagenicity studies, a conserva-
tive default factor of 10 was used i.e. a short-term rodent study
lasting less than 3 months (ICH, 2017). Further work in this area is
needed to evaluate variables such as chronic vs. acute exposures in
the TGR assay.
• F4: severity of effect. Since both mutation and cancer are consid-
ered irreversible severe effects, a maximum value of 10 was used
((R7) IQC, 2018).
• F5: factor to compensate for database insufficiency (e.g., cases
where a NOEL cannot be determined). This was set to 1 because
the analyses are based on a BMDL values, which is considered a
superior metric.
Overall, the combined UFs for both PDEs calculations were 5000
for mutagenicity and 500 for carcinogenicity, respectively. Further
research to refine adjustment factor values could in time change in
overall PDE value defined from the TGR data (White et al., 2020), with
F2, F3, and F4 being the most open for modification based on
increased understanding of biology and translation.
3 | RESULTS
Figure 1 shows the results of the BMD analysis for BigBlue rat lacI
mutant frequency dose–response data (Gollapudi et al., 1998). The data
were analyzed using both lacI and cII gene mutation frequencies;
analyses of the lacI dose–response data provided the lower, more con-
servative BMDL while still maintaining suitable precision (i.e., BMDL:
BMD upper bound [BMDU] ratio < 100) (White et al., 2020). The ana-
lyses of the carcinogenicity dose–response data (Figure 2) yielded a very
precise BMD (i.e., a ratio of the upper and lower estimates of BMD,
BMDL:BMDU of <2). This same precision was also seen for the NDEA
BMDL:BMDU ratios, with a higher ratio for the mutagenicity dose–
response data (Figure 3) compared with the carcinogenicity dose–
response data (Figure 4). The high BMDL:BMDU ratios for the NDMA
TGR data, are potentially linked to the study designs being sub-optimal
for dose response analysis. All BMD CIs are presented in Table 1.
PDE values calculated using carcinogenicity and mutagenicity
BMD values (i.e., PDEcancer and PDEmutation, respectively) are shown in
Table 1. Interestingly, the mutation PDEs are lower than those derived
from carcinogenicity data. Higher sensitivity of mutation assays might
be expected because mutations are predicted to occur at earlier
timepoints and lower doses than cancer along the AOP, and not all
mutations will progress to form tumors. However, the PDE also
reflects the use of UFs that were 10 times higher in the mutation data
calculations (i.e., 5000 for PDEmutation and 500 for PDEcancer; Table 1).
The difference was in the use of an F3 (treatment duration adjustment
factor) of 10 for the mutation data and 1 for cancer data. The conser-
vative nature of F3, could be considered as 1, if the 28 day study
design was accepted as sufficient in order to assess mutation.
4 | DISCUSSION
Since the NDMA contamination issue in 2018, NDMA, NDEA, and
the whole class of nitrosamines have received extensive regulatory
F IGURE 1 BMD analysis of in vivo transgenic gene mutation in Big Blue rats at the LacI locus (Gollapudi et al., 1998). PROAST v69.2 was
used to assess the BMD at CES 50% using the exponential (Expon. m3-) and Hill (Hill m3-) models. The three-parameter models provided suitable
fit to the data. The x-axes denote dose of NDMA administered and the y-axes show MF. The triangles represent the replicate data points. BMD,
benchmark dose; CES, critical effect size; MF, mutant frequency; NDMA, N-nitrosodimethylamine
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attention. Regulatory risk assessment applied the default linear
extrapolation approach from the harmonic mean TD50 from multiple
tumorigenicity studies have resulted in AIs of 96 ng/day for NDMA
and 26.5 ng/day for NDEA, respectively (EMA, 2020a; EMA, 2020b;
FDA, 2021). NDMA and NDEA are the N-nitrosamines that are the
most characterized in non-clinical safety animal models, and they are
also regarded as among the more potent N-nitrosamine compounds
based on TD50 values (FDA, 2021). By way of comparison, these AI
values calculated using TD50 values, are 65-fold and 83-fold lower
than the cancer PDEs calculated in the present report for NDMA and
NDEA, respectively. It is also noteworthy that AI from linear extrapo-
lation, were also calculated using BMDL10 values at 135-215 ng/day
for NDMA (EC, 2012; EMA, 2019), and 90 ng/day for NDEA
(EC, 2012). The cancer AIs from TD50 values are 6-fold and 1.5-fold
lower than the calculated mutation PDEs for NDMA and NDEA,
respectively. A major contributing factor to the differences observed
F IGURE 2 BMD analysis of liver cancer data in Colworth/Wistar rats following exposure to NDMA (Peto et al., 1991). PROAST v70.0 was
used to assess the BMD at CES 10% using the nine default quantal data models of two-stage, log-probit, probit, log-logistic, logistic, gamma,
exponential, Weibull, and Hill. BMD analysis of the hepatic carcinogenicity dose–response data from table 7 of Peto et al. (1991). The dashed line
is the BMD10. PROAST online (https://proastweb.rivm.nl/) was used with model averaging to calculate the BMD CI bounds (BMDL10 = 0.062,
0.107 mg/kg). A complete summary of the results of the carcinogenicity BMD analyses is presented in Table S1. For completeness, analysis of the
female dose–response data resulted in BMD CI bounds of BMDL10 = 0.283 and 0.367 mg/kg. The x-axes denote dose of NDMA administered
and the y-axes show increased incidence of “liver cell” tumors, as a fraction of total study population. The default number of bootstrap runs (200)
was used to calculate BMD CIs (EFSA, 2019). BMD, benchmark dose; BMDL, benchmark dose lower bound; CES, critical effect size; CI,
confidence interval; NDMA, N-nitrosodimethylamine
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between the AI and PDE values, is the linear assumption and un-
refined default factor of 100,000 used within the AI, compared to the
non-linear assumptions, and refined adjustment factors within
the PDE. Furthermore, although standard TTC values are not applica-
ble for these nitrosamines listed in the cohort of concern (ICH, 2017),
it is interesting to show that the cancer-derived PDEs for NDMA and
NDEA are both higher than the default TTC value of 1.5 μg/person/
day, but the mutation-derived PDEs are lower than the TTC because
of the use of a high UF applied based on the short-term exposure
duration of the TGR assays.
We consider that the application of the BMD should inform
how N-nitrosamines and other DNA-reactive mutagens are assessed
for regulatory purposes. In order for health authorities to support a
move from the use of TD50 values for linear extrapolation for risk
assessment toward the PDE approach for NDMA, NDEA, and other
nitrosamines, there is a need for robust evidence around the under-
lying mechanisms by which alkylating nitrosamines cause DNA dam-
age and cancer at low concentrations. A “threshold mechanism”
with a clear PoD has been clearly presented for many alkylating
agents (Muller et al., 2009; Muller & Gocke, 2009). Although
chemicals such as NDMA and NDEA have quite diverse adducts
spectrums, the most mutagenic and prevalent adducts are those
detailed above. These DNA adducts are subject to mechanism-based
thresholds linked to DNA repair, especially in the low dose region
often exemplified by human exposures to impurities in pharmaceuti-
cal preparations.
The existence of mechanisms leading to a dose response that is
nonlinear or have a practical threshold is increasingly recognized, not
only for compounds that interact with non-DNA targets but also for
DNA-reactive compounds, whose effects may be modulated by, for
example, rapid detoxification before coming into contact with DNA or
by effective repair of induced damage (Kobets & Williams, 2019). The
regulatory approach to such compounds can be based on the identifi-
cation of a NOEL and use of UFs (ICHQ3C[R6], reference 7 therein)
to calculate a PDE when data are available (ICH, 2017). The impact of
DNA repair on the potency of DNA-reactive mutagens is discussed in
White et al. (2020), in which the BMDL was lower when DNA repair
was knocked down across every study investigated. Additional studies
using a mammalian gene mutation endpoint along with DNA repair
knockdown would support the impact of DNA repair on the potency
of NDMA and NDEA, as previously shown using a bacterial gene
mutation endpoint (Arimoto-Kobayashi et al., 1997). There are exten-
sive data for this on potent mutagens with similar adduct and muta-
tion profiles in mammalian cells, including methylnitronitrosoguanidine
(MNNG) and MNU (Beranek, 1990; Jenkins et al., 2005; Kaina
et al., 1991).
For alkylating nitrosamines, gene mutation is the type of genetic
damage most linked to cancer. Therefore, in the absence of cancer
data, in vivo mutagenicity data would be the preferred endpoint for
calculation of a HBGV (EMA, 2020b; EMA, 2020c).
With respect to the levels of NDMA in valsartan tablets (which
varied to levels ≤20 μg/day), based on the aforementioned BMD
and PDE modeling approach, the calculated mutagenicity PDE
alone would indicate that certain batches of 320-mg valsartan tab-
lets that contained levels of NDMA that would not represent a the-
oretical mutagenicity risk and hence an increased theoretical excess
F IGURE 3 BMD covariate analysis of in vivo transgenic gene mutation in F344/gpt delta rats at the gpt locus using sampling time (2, 4, and
8 weeks) as the covariate (Akagi et al., 2015). PROAST v69.2 was used to assess the BMD at CES 50% using the exponential (Expon. m5-a) and
Hill (Hill m5-a) models. The triangles represent the replicate data points. The different colors represent the different timepoints within 2 strains of
gpt delta rats in liver; black, F344 2-weeks; blue, SD 2-weeks; red, F344 4-weeks; turquoise, SD 4-weeks; green, F344 8-weeks; SD 8-weeks. The
three-parameter models provided suitable fit to the data. BMD, benchmark dose; CES, critical effect size
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cancer risk in the human population. Likewise, the calculated carci-
nogenicity PDE would also indicate that numerous batches of
320-mg valsartan tablets contain levels of NDMA that would not
represent an increase in the theoretical excess cancer risk in the
human population.
An outcome of this study is a potential framework for how muta-
tion data can be used for human health risk assessments, with a focus
on potent mutagenic impurities. Progress has been made in using the
BMD approach on mutagenicity data to calculate PoD (Gollapudi
et al., 2013; Johnson et al., 2014; MacGregor et al., 2015a), and also
F IGURE 4 BMD analysis of liver cancer data in Colworth/Wistar rats following exposure to NDEA (Peto et al., 1991) . PROAST v70.0 was
used to assess the BMD at CES 10% using the nine default quantal data models of two-stage, log-probit, probit, log-logistic, logistic, gamma,
exponential, Weibull, and Hill. BMD analysis of the hepatic carcinogenicity dose–response data from table 7 of Peto et al. (1991). PROAST online
(https://proastweb.rivm.nl/) was used with model averaging to calculate the BMD CI bounds (BMDL10 = 0.022, 0.046 mg/kg). The dashed line is
the BMD10. A complete summary of the results of the carcinogenicity BMD analyses is presented in Table S2. For completeness, analysis of the
female dose–response data resulted in BMD CI bounds of BMDL10 = 0.023 and 0.041 mg/kg. The x-axes denote dose of NDEA administered
and the y-axes show increased incidence of “liver cell” tumors, as a fraction of total study population. The default number of bootstrap runs (200)
was used for calculating BMD CIs (EFSA, 2019). BMD, benchmark dose; BMDL, benchmark dose lower bound; CES, critical effect size; CI,
confidence interval; NDEA, N-nitrosodiethylamine
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around the understanding that mutation is a relevant endpoint for
human health risk assessment (Heflich et al., 2020). However, further
work is needed to solidify the guidance, particularly on selection of
the adjustment factors (White et al., 2020). Approaches such as the
approximate probabilistic analysis (APROBA) can be used to account
for uncertainty in the HBGV (EPA, 2000; International Programme
on Chemical Safety, 2014; White et al., 2020), and their application
to mutagenicity data is of major interest in developing the use of
these data for protecting the human population from additional cancer
risk. The PDEs derived from the mutagenicity dose–response data
(Table 1) were determined using a conservative composite UF of 5000.
There is currently no agreed basis for selection of appropriate UF
values for interpretation of in vivo genetic toxicity dose–response data.
White et al. (2020) show a suggested approach for defining these fac-
tors with some potential to reduce the values of the UFs used in this
report. Through this suggested approach, those in the population with
conditions such as DNA repair deficiency are protected. This work is
being expanded upon, to refine and solidify guidance for recommenda-
tions of factors for use within genetic toxicity-based risk assessments.
Our current approach uses the most conservative factors, leaving future
opportunities to refine the values for use in calculating genetic toxicity
driven PDEs.
Detailed considerations of options for each factor are beyond the
scope of this work, although international expert groups, including
the Health and Environmental Sciences Institute Genetic Toxicology
Technical Committee and the 2021 International Workshop on Gen-
otoxicity Testing, intend to address this task and provide further guid-
ance in due course.
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